MX2015003124A - Formas polimorficas de enzalutamida y su preparacion. - Google Patents

Formas polimorficas de enzalutamida y su preparacion.

Info

Publication number
MX2015003124A
MX2015003124A MX2015003124A MX2015003124A MX2015003124A MX 2015003124 A MX2015003124 A MX 2015003124A MX 2015003124 A MX2015003124 A MX 2015003124A MX 2015003124 A MX2015003124 A MX 2015003124A MX 2015003124 A MX2015003124 A MX 2015003124A
Authority
MX
Mexico
Prior art keywords
enzalutamide
preparation
polymorphic forms
present application
relates
Prior art date
Application number
MX2015003124A
Other languages
English (en)
Inventor
Vishweshwar Peddy
Rajesham Boge
Rao Madivada Lokeswara
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Publication of MX2015003124A publication Critical patent/MX2015003124A/es

Links

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
    • H04W12/06—Authentication
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L65/00—Network arrangements, protocols or services for supporting real-time applications in data packet communication
    • H04L65/10—Architectures or entities
    • H04L65/1016—IP multimedia subsystem [IMS]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L65/00—Network arrangements, protocols or services for supporting real-time applications in data packet communication
    • H04L65/1066—Session management
    • H04L65/1073—Registration or de-registration
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L65/00—Network arrangements, protocols or services for supporting real-time applications in data packet communication
    • H04L65/40—Support for services or applications
    • H04L65/4061—Push-to services, e.g. push-to-talk or push-to-video
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L9/00—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols
    • H04L9/40—Network security protocols
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
    • H04W12/06—Authentication
    • H04W12/069—Authentication using certificates or pre-shared keys
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
    • H04W12/08—Access security
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
    • H04W12/08—Access security
    • H04W12/086—Access security using security domains
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/06—Selective distribution of broadcast services, e.g. multimedia broadcast multicast service [MBMS]; Services to user groups; One-way selective calling services
    • H04W4/10—Push-to-Talk [PTT] or Push-On-Call services
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/90—Services for handling of emergency or hazardous situations, e.g. earthquake and tsunami warning systems [ETWS]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W60/00—Affiliation to network, e.g. registration; Terminating affiliation with the network, e.g. de-registration
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W60/00—Affiliation to network, e.g. registration; Terminating affiliation with the network, e.g. de-registration
    • H04W60/005—Multiple registrations, e.g. multihoming
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W76/00—Connection management
    • H04W76/40—Connection management for selective distribution or broadcast
    • H04W76/45—Connection management for selective distribution or broadcast for Push-to-Talk [PTT] or Push-to-Talk over cellular [PoC] services
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W76/00—Connection management
    • H04W76/50—Connection management for emergency connections

Landscapes

  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Multimedia (AREA)
  • Computer Security & Cryptography (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Business, Economics & Management (AREA)
  • Public Health (AREA)
  • General Business, Economics & Management (AREA)
  • Environmental & Geological Engineering (AREA)
  • Emergency Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La solicitud actual se refiere a formas cristalinas y amorfas de Enzalutamida. La solicitud actual se refiere además a dispersiones sólidas amorfas de Enzaluitamida con portadores farmacéuticamente aceptables. La solicitud actual también se refiere a un proceso para la preparación de la Forma R1 de Enzalutamida.
MX2015003124A 2012-09-11 2013-09-11 Formas polimorficas de enzalutamida y su preparacion. MX2015003124A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3772CH2012 2012-09-11
PCT/IB2013/058455 WO2014041487A2 (en) 2012-09-11 2013-09-11 Enzalutamide polymorphic forms and its preparation

Publications (1)

Publication Number Publication Date
MX2015003124A true MX2015003124A (es) 2015-10-12

Family

ID=50278792

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003124A MX2015003124A (es) 2012-09-11 2013-09-11 Formas polimorficas de enzalutamida y su preparacion.

Country Status (14)

Country Link
US (3) US20150239848A1 (es)
EP (1) EP2895464A4 (es)
JP (1) JP2015534550A (es)
KR (1) KR20150053963A (es)
CN (1) CN104768935A (es)
AU (1) AU2013316754A1 (es)
BR (1) BR112015005404A2 (es)
CA (1) CA2884640A1 (es)
IL (1) IL237668A0 (es)
IN (1) IN2015CH01921A (es)
MX (1) MX2015003124A (es)
RU (1) RU2015113434A (es)
WO (1) WO2014041487A2 (es)
ZA (1) ZA201502336B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3725778T3 (da) 2012-09-11 2021-09-20 Medivation Prostate Therapeutics Llc Formuleringer af enzalutamid
CN103910679B (zh) * 2014-04-23 2016-05-25 杭州新博思生物医药有限公司 一种恩杂鲁胺的制备方法
US20170190670A1 (en) * 2014-07-11 2017-07-06 Shilpa Medicare Limited Improved process for the preparation of enzalutamide
CN104356068A (zh) * 2014-10-30 2015-02-18 杭州新博思生物医药有限公司 恩杂鲁胺新晶型及其制备方法
EP3284277A4 (en) 2015-04-02 2018-04-18 Samsung Electronics Co., Ltd. Method for performing multiple authentications within service registration procedure
CN106146403B (zh) * 2015-04-02 2018-11-20 正大天晴药业集团股份有限公司 一种恩杂鲁胺的纯化方法
KR102666017B1 (ko) * 2015-05-29 2024-05-16 아스텔라스세이야쿠 가부시키가이샤 엔잘루타미드 결정형의 제조 방법
CN105030685B (zh) * 2015-07-21 2018-02-27 福格森（武汉）生物科技股份有限公司 一种恩杂鲁胺固体分散体口服制剂
PT3348546T (pt) * 2015-09-10 2020-05-29 Jiangsu Hengrui Medicine Co Forma cristalina de um inibidor de recetor de androgénio e o seu método de preparação
US11478453B2 (en) 2016-07-21 2022-10-25 Hadasit Medical Research Services And Development Ltd. Treatment for glioblastoma
CN110573153B (zh) 2017-04-28 2023-04-04 安斯泰来制药有限公司 含有恩杂鲁胺的口服给药用药物组合物
CN111386257B (zh) * 2017-11-28 2024-05-24 阿尔第药物实验室有限公司 使用新中间体制备恩杂鲁胺的方法
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
KR20210124333A (ko) * 2019-02-01 2021-10-14 치아타이 티안큉 파마수티컬 그룹 주식회사 디아릴티오히단토인 화합물의 결정형
CN110981812A (zh) * 2019-11-25 2020-04-10 奥锐特药业股份有限公司 一种无定形恩杂鲁胺的制备方法
CN111217757B (zh) * 2020-01-06 2021-03-19 武汉大学 一种恩杂鲁胺化合物及其药物组合物制剂
CN111303042A (zh) * 2020-03-25 2020-06-19 北京赛思源生物医药技术有限公司 一种恩杂鲁胺的新晶型
WO2024153733A1 (en) 2023-01-18 2024-07-25 Helm Ag Crystalline nanoparticles comprising enzalutamide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
IN191496B (es) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US20050020675A1 (en) 2003-02-21 2005-01-27 Parthasaradhi Reddy Bandi Bicalutamide polymorphs
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
NZ591119A (en) * 2005-05-13 2012-08-31 Univ California Use of diarylhydantoin compounds for treating specific cancers
JP5350217B2 (ja) 2006-03-29 2013-11-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールチオヒダントイン化合物
DK2538785T3 (en) * 2010-02-24 2018-05-22 Medivation Prostate Therapeutics Llc Methods for the synthesis of diarylthiohydantoin and diarylhydantoin compounds

Also Published As

Publication number Publication date
KR20150053963A (ko) 2015-05-19
WO2014041487A3 (en) 2014-05-22
WO2014041487A2 (en) 2014-03-20
US20170029380A1 (en) 2017-02-02
US20150239848A1 (en) 2015-08-27
RU2015113434A (ru) 2016-11-10
JP2015534550A (ja) 2015-12-03
IN2015CH01921A (es) 2016-07-01
AU2013316754A1 (en) 2015-04-30
BR112015005404A2 (pt) 2017-08-22
CA2884640A1 (en) 2014-03-20
IL237668A0 (en) 2015-04-30
ZA201502336B (en) 2016-02-24
EP2895464A4 (en) 2016-06-15
US20170267645A1 (en) 2017-09-21
CN104768935A (zh) 2015-07-08
US9701641B2 (en) 2017-07-11
EP2895464A2 (en) 2015-07-22

Similar Documents

Publication Publication Date Title
MX2015003124A (es) Formas polimorficas de enzalutamida y su preparacion.
HK1196849A1 (en) Recombinant microorganism for the production of useful metabolites
IL229656A0 (en) A process for the preparation of crystalline dimethyl fumarate with a high level of purity
EP2743336A4 (en) PROCESS FOR THE PRODUCTION OF HIGH-PURITY BIODIESEL
SG11201404870YA (en) Process for the preparation of polypropylene with low ash content
HK1199882A1 (zh) 用於製備雌四醇的方法
IN2013CN09704A (es)
HUE049168T2 (hu) L-aminosav elõállítására képes mikroorganizmus és eljárás L-aminosav elõállítására annak alkalmazásával
SG11201402949RA (en) Process for producing nutrient composition
PL2785701T3 (pl) Krystaliczna postać kabazytakselu i sposób jej otrzymywania
WO2012015999A3 (en) Process for the preparation of imatinib mesylate
WO2012018791A3 (en) Preparation of prasugrel hydrochloride
IN2014DN09451A (es)
WO2011100282A3 (en) Imatinib mesylate polymorphs
EP2694621B8 (en) Methods for the production of fuel
IL218764A0 (en) Crystalline levofolinic acid and process for its preparation
HRP20160767T1 (hr) Postupak za pripremu kristalnog oblika i agomelatina
IN2012CH02984A (es)
MX2013002990A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
AU2011903743A0 (en) Technology suite for to facilitate the process of removals
IN2013CH03945A (es)
IN2013MU02612A (es)
WO2013124868A3 (en) Solid form of aliskiren intermediate
WO2014024210A3 (en) Novel polymorphs of doxercalciferol
EP2730577A4 (en) CRISTILLINE MODIFICATION OF A PARA-METHOXYANILIDE OF 6-HYDROXY-4-OXO-2,4DIHYDRO-1N-PYRROLO- [3.2.1, IJ] QUINOLINE-5-CARBONIC ACID